Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Twas the Night Before Alibaba (BABA)
- Market Wrap: CEO Retirement Party; SAP's Big Purchase; Home Depot Outlines Card Breach, Outlook
- Oracle (ORCL) CEO Ellison Steps Down; Will Remain as Chairman
- After-Hours Stock Movers 9/18 (CNQR) (MCP) (JBLU) Higher; (TIBX) (RHT) (ORCL) Lower (more...)
- SAP (SAP) to Acquire Concur Technologies (CNQR) for $129/Share
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
You May Also Be Interested In
- Vimicro (VIMC) Is Maybe the Hottest Stock in the Market
- Nektar Therapeutics (NKTR) Wins FDA Approval of Movanik
- Heat Biologics (HTBX) Commences Dosing in HS-110 Phase 2
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!